Sign In
Buy MIRM
$91.84
-0.335 (-0.363%)
At Close: Jun 03, 2026
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
08:30am, Thursday, 10'th Oct 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #pbc--Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:45pm, Tuesday, 10'th Sep 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?
12:37pm, Friday, 06'th Sep 2024
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
04:01pm, Wednesday, 28'th Aug 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel the
Mirum (MIRM) Banks on Livmarli, Overdependence a Concern
12:11pm, Monday, 19'th Aug 2024
Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further.
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call Transcript
09:10pm, Friday, 09'th Aug 2024
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2024 Results Conference Call August 7, 2024 4:30 PM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief Execu
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00pm, Friday, 09'th Aug 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top
12:06pm, Thursday, 08'th Aug 2024
Mirum's (MIRM) earnings miss estimates in the second quarter of 2024 while revenues beat the same. Livmarli drives year-over-year sales.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
06:25pm, Wednesday, 07'th Aug 2024
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.92 per share a year ago.
Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
04:30pm, Wednesday, 31'st Jul 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024.
Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?
08:30am, Monday, 29'th Jul 2024
Mirum Pharmaceuticals (MIRM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt
Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition
03:48am, Wednesday, 17'th Jul 2024
Mirum Pharmaceuticals develops therapies for rare liver diseases, focusing on bile acid regulation. Key products include Livmarli, Cholbam, and Chenodal, with Chenodal recently completing Phase 3 tria
Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
11:42am, Tuesday, 09'th Jul 2024
The European Commission approves Mirum's (MIRM) Livmarli for the treatment of progressive familial intrahepatic cholestasis in patients three months of age and older.
Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why
12:40pm, Monday, 08'th Jul 2024
The recent label expansion of Mirum's (MIRM) lead drug, Livmarli, is expected to drive sales in the upcoming quarters. The company's efforts to build its pipeline beyond Livmarli also hold promise.
3 Biotech Stocks For The Second Half Of 2024
04:48pm, Thursday, 27'th Jun 2024
3 Biotech Stocks For The Second Half Of 2024
